ERBB2 and non-small cell lung carcinoma: The molecular signatures observed in SCLC are distinct compared to those found in NSCLC, where a range of oncogenic driver mutations/fusions are prevalent, such as EGFR, KRAS, ALK, BRAF, RET, ROS1, MET, NTRK1-3, and HER2/ERBB2 [3,35,95].